CAH vs SKYE · P/E 35, rev $254.25B vs $25.0M cap
Cardinal Health Inc (CAH) versus Skye Bioscience, Inc. Common Stock (SKYE) — a side-by-side from cached financials, not a winner call.
Cardinal Health Inc (CAH) is a medical distribution company listed on NYSE.
Skye Bioscience, Inc. Common Stock (SKYE) is a biotechnology company listed on NASDAQ.
Latest reported CAH revenue for 2026-06-30 was $254.25B. Net income was $1.71B. Revenue was up 14.2% from 2025-06-30 to 2026-06-30. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
SKYE does not have a complete income-statement cache yet.
CAH currently screens at market cap $53.00B and trailing P/E 34.6. SKYE currently screens at market cap $25.0M.
Not investment advice. Open the CAH and SKYE stock pages for the full models.
Not investment advice.